Neumora Therapeutics reported total assets of $125.25M and total liabilities of $80.73M for the quarter ended Jun 2026, down 44.0% year over year. This balance sheet covers 16 quarters of results from Sep 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Current Assets | ||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 252.51M | 240.94M | 210.87M | 204.22M | 412.28M | 374.04M | 182.93M | 150.68M | 275.71M | 142.15M | 126.86M | 124.52M | 129.07M | 182.53M | 147.07M | 116.83M |
| Receivables - OtherOther Receivables | 0.92M | 0.67M | 0.94M | 0.91M | 1.63M | |||||||||||
| Prepaid Assets | 16.02M | 16.17M | 24.30M | 20.07M | 26.68M | 6.09M | 5.26M | 4.30M | 5.32M | 5.56M | 8.01M | 6.36M | 8.04M | |||
| Current Assets | 387.95M | 525.74M | 478.28M | 442.79M | 398.32M | 348.61M | 314.06M | 254.87M | 222.91M | 177.08M | 190.54M | 153.43M | 124.87M | |||
| Non-Current Assets | ||||||||||||||||
| Property, Plant & Equipment (Net) | 2.41M | 1.93M | 1.79M | 1.64M | 1.48M | 1.30M | 1.14M | 0.98M | 0.09M | 0.08M | 0.04M | 0.03M | 0.03M | |||
| Long-Term Investments | 23.51M | 9.91M | 9.85M | 0.30M | ||||||||||||
| Other Non-Current Assets | 1.26M | 1.26M | 1.21M | 1.21M | 1.21M | 1.21M | 1.21M | 1.21M | 1.21M | 1.21M | 1.21M | 0.30M | 0.20M | 0.05M | 0.05M | 0.05M |
| Non-Current Assets | 38.28M | 19.01M | 17.92M | 7.43M | 6.15M | 3.93M | 2.92M | 1.88M | 0.92M | 0.75M | 0.51M | 0.44M | 0.38M | |||
| Assets | 426.23M | 544.75M | 496.19M | 450.21M | 404.47M | 352.54M | 316.97M | 256.75M | 223.82M | 177.83M | 191.05M | 153.88M | 125.25M | |||
| Liabilities | ||||||||||||||||
| Current Liabilities | ||||||||||||||||
| Accounts Payables | 7.15M | 2.23M | 0.34M | 1.49M | 1.08M | 6.11M | 3.31M | 1.05M | 0.64M | 0.55M | 3.38M | 5.06M | 4.15M | |||
| Payables | 7.15M | 2.23M | 0.34M | 1.49M | 1.08M | 6.11M | 3.31M | 1.05M | 0.64M | 0.55M | 3.38M | 5.06M | 4.15M | |||
| Accumulated Expenses | 11.54M | 23.35M | 21.26M | 19.49M | 18.30M | 22.76M | 24.59M | 26.27M | 20.25M | 24.98M | 28.79M | 24.77M | 23.33M | |||
| Other Accumulated Expenses | 0.41M | 0.38M | 0.75M | 0.54M | 0.37M | 0.39M | 0.33M | 0.41M | 0.45M | 0.45M | 0.72M | 0.74M | 0.57M | |||
| Current Leases | 3.37M | 3.40M | 3.38M | 3.49M | 3.61M | 2.75M | 1.85M | 0.94M | 0.17M | 0.26M | 0.28M | 0.29M | 0.30M | |||
| Total Current Liabilities | 23.70M | 29.12M | 25.11M | 24.61M | 23.12M | 31.74M | 29.89M | 28.38M | 21.16M | 25.84M | 32.45M | 30.11M | 27.78M | |||
| Non-Current Liabilities | ||||||||||||||||
| Non-Current Debt | 19.45M | 19.56M | 54.53M | 52.96M | 52.91M | |||||||||||
| Preferred Stock Liabilities | 817.10M | 843.69M | 843.69M | 843.69M | ||||||||||||
| Operating Leases | 5.07M | 2.75M | 1.85M | 0.94M | 0.34M | 0.27M | 0.19M | 0.12M | 0.04M | |||||||
| Total Liabilities | 422.00M | 29.40M | 477.92M | 513.54M | 32.06M | 27.12M | 25.67M | 23.21M | 31.80M | 29.91M | 28.38M | 40.95M | 45.67M | 87.18M | 83.20M | 80.73M |
| Shareholder's Equity | ||||||||||||||||
| Total Debt | 19.45M | 19.56M | 54.53M | 52.96M | 52.91M | |||||||||||
| Common Equity | -422.00M | -446.85M | -477.92M | -513.54M | 512.69M | 469.08M | 424.54M | 381.26M | 320.74M | 287.06M | 228.36M | 182.88M | 132.16M | 103.87M | 70.68M | 44.52M |
| Liabilities and Shareholders Equity | 426.23M | 544.75M | 496.19M | 450.21M | 404.47M | 352.54M | 316.97M | 256.75M | 223.82M | 177.83M | 191.05M | 153.88M | 125.25M | |||
| Retained Earnings | -467.51M | -594.70M | -703.43M | -757.15M | -815.86M | -888.40M | -947.22M | -1015.21M | -1067.94M | -1124.70M | -1184.15M | -1237.61M | -1280.69M | |||
| Treasury Shares | 102.14M | 104.42M | 104.42M | 104.42M |